Literature DB >> 18753759

Safer cordocentesis by new 25-gauge needles.

Yuichi Kawakami1, Hideo Matsuda, Tomoko Shibasaki, Masashi Yoshida, Kenichi Furuya.   

Abstract

OBJECTIVE: The objective of this study was to establish safer cordocentesis by using newly produced 25-gauge needles rather than the needles currently used.
METHODS: Human umbilical cords were preserved in experiment 1. Pinching both ends, cordocenteses were performed by filling the cord with saline inside the sphere of the pressure-equilibrated Ringer's solution bag in an aquarium. Pressure alterations were recorded before and after the cordocenteses (n = 5 in each needle) using 22-, 23-, and 25-gauge needles. In experiment 2, human umbilical blood after delivery was preserved. Umbilical blood was drawn in syringes, and fixed in syringe infusion pumps of 150 ml/h. The blood (n = 8) was then pushed into the test tubes through 22-, 23-, and 25-gauge needles. Hemolysis and platelet activation were evaluated. As in the case of clinical data, non-stress tests (NST) subsequent to cordocenteses were compared between 23-gauge (n = 19) and 25-gauge (n = 16) needles.
RESULTS: In experiment 1, the 25-gauge cordocenteses documented a more favorable pressure curve than other needles. In experiment 2, no statistical significance was observed for plasma-free hemoglobin, total bilirubin, hemoglobin, AST, LDH, potassium, platelet count, beta-thromboglobulin, and platelet factor IV. As in the case of clinical data, NSTs subsequent to cordocenteses revealed strong significance in the duration to recover variability (p = 0.0003) and the duration to recover acceleration (p = 0.0033).
CONCLUSION: We concluded that 25-gauge needles appear superior in avoiding blood loss in the leaking phase. Although blood drawing takes time in the sampling phase, no hemolysis or platelet activation was observed. NST proved that 25-gauge cordocenteses showed favorable patterns. We propose that use of 25-gauge needles is promising under appropriate procedures in cordocentesis. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2008        PMID: 18753759     DOI: 10.1159/000151340

Source DB:  PubMed          Journal:  Fetal Diagn Ther        ISSN: 1015-3837            Impact factor:   2.587


  1 in total

1.  Successful treatment of fetal intraperitoneal administration of immunoglobulin in a case of fetal hemolytic anemia with 131,072-fold anti-e alloimmunization.

Authors:  Masashi Yoshida; Hideo Matsuda; Eijiro Hayata; Akio Watanabe; Miho Oeda; Kenichi Furuya
Journal:  Case Rep Obstet Gynecol       Date:  2011-11-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.